アオキ ユウジ
Yuji.AOKI
青木 雄次
- 所属 松本大学大学院 健康科学研究科 健康科学専攻
- 松本大学 人間健康学部 健康栄養学科
- 職種 教授
| 言語種別 | 英語 |
| 発行・発表の年月 | 2015/10 |
| 形態種別 | 総説・解説（その他） |
| 招待論文 | 招待あり |
| 標題 | Surprising results of the EMPA-REG OUTCOME study have brought a new insight into use of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes. |
| 執筆形態 | 単著 |
| 掲載誌名 | Tropical Medicine & Surgery |
| 掲載区分 | 国外 |
| 巻・号・頁 | 3(4) |
| 総ページ数 | 2 |
| 担当範囲 | All |
| 著者・共著者 | Yuji Aoki |
| 概要 | A surprising new study EMPA-REG OUTCOME has shown that empagliflozin, one of sodium-glucose cotransporter 2 (SGLT2) inhibitors, in addition to standard care had beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for cardiovascular events. Its ability to reduce cardiovascular mortality may be mediated through osmotic diuresis. Such action of SGLT2 inhibitors seems to be rather close to that of tolvaptan to promote water diuresis, and SGLT2 inhibitors could be used as a new oral osmotic diuretic. |